Regional aspects of associations of the CYP2C19 gene polymorphism with coronary atherosclerosis in acute coronary syndrome

Aim. To study the associations of allelic variants of the CYP2C19 gene with atherosclerotic lesions of the coronary arteries in patients with acute coronary syndrome (ACS) in the North of Siberia (Surgut) and in large cities of the Siberian Federal Okrug (SFO).

Material and methods. During the study 296 patients with ACS were examined at admission to cardiology hospitals in large cities of the North (Surgut, 114 patients) and SFO (Irkutsk and Kemerovo, 182 patients). All patients underwent coronary angiography and genetic research (identification of CYP2C19*2, CYP2C19*3 and CYP2C19*17 alleles).

Results. In patients with ACS living in the North of Russia allelic variant CYP2C19*17 (*17/*17) is positively associated with the severity of lesion of left coronary artery (LCA) (χ²=9,81; p=0,002), as well as with at least 50% stenosis, more than 70% lesion of the proximal or middle part of the three main arteries, or more than 50% lesion of LCA trunk (χ² =6,52; p=0,011), and previous myocardial infarction (χ²=8,15; p=0,004). Among patients with ACS living in cities of the Siberian Federal Okrug, the allelic variant CYP2C19*17 (*17/*17) is directly associated with diabetes mellitus (χ²=5,48; p=0,019) and less than 45% left ventricular ejection fraction (χ²=4,20; p=0,040). Regression analysis showed that in patients with ACS living in the northern region of Russia, only the allelic variant CYP2C19*17 (*17/*17) correlated with at least 50% stenosis of LCA trunk (Exp (B): 11,623, 95% CI: 1,893; 71,342; p=0,008). It did not correlate with the male sex, age, smoking and diabetes (p>0,05).

Conclusion. The results show the presence of direct associations of CYP2C19*17 alleles with prognostically unfavorable coronary atherosclerosis in ACS patients living in the North of Siberia.

1. Golukhova EZ, Ryabinina MN, Bulaeva NI, et al. Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am. J. Ther. 2015;22:3:222-30. doi:10.1097/MJT.0000000000000125.

2. Knauer NJu, Lifshits GI, Voronina EN, et al. Informativeness of genetic markers for optimization of personalized treatment with clopidogrel. Саrdilogy. 2013;8:72-5. (In Russ.).

3. Mirzaev KB, Zelenskaya EM, Barbarash OL, et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med. 2017;10:107-14. doi:10.2147/PGPM.S126305.

4. Daoulah A, Elkhateeb OE, Nasseri SA, et al. Socioeconomic Factors and Severity of Coronary Artery Disease in Patients Undergoing Coronary Angiography: A Multicentre Study of Arabian Gulf States. Open Cardiovasc Med J. 2017;11:47-57. doi:10.2174/1874192401711010047.

5. Mirzaev KB, Zelenskaya EM, Barbarash OL, et al. Carrying frequency of clinically significant alleles of CYP2C19 gene in patients with acute coronary syndrome from Central, Eastern, Northern Siberia and Moscow region. Creative Cardiology. 2017;11:1:8- 19. (In Russ.). doi:10.15275/kreatkard.2017.01.02.

6. Volumes of the official publication of results of the all-Russian population census of 2010. Volume 4. National composition and language skills, citizenship: 742-845. (In Russ.). http://www.gks.ru/free_doc/new_site/perepis2010/croc/perepis_itogi1612.htm (11 Мау 2018).

7. Ercan B, Ayaz L, Cicek D, Tamer L. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem. Funct. 2008;26:3:309-13. doi: 10.1002/cbf.1437.

8. Akasaka T, Sueta D, Arima Y, et al. Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. Am. J. Physiol. Heart Circ. Physiol. 2016;311:6:1409-15. doi:10.1152/ajpheart.00473.2016.

9. Tabata N, Hokimoto S, Akasaka T, et al. Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation. J. Cardiol. 2016;67:1:104-9. doi:10.1016/j.jjcc.2015.03.010.

10. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588. doi:10.1136/bmj.d4588.

11. Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98:2:100-8. doi:10.1136/hrt.2011.227652.

12. Gaio V, Nunes B, Fernandes A, et al. Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal. Diabetol Metab Syndr. 2014;6:23. doi:10.1186/1758-5996-6-23.

13. Martlnez-Quintana E, Rodriguez-Gonzalez F, Medina-Gil JM, et al. CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome. Med Clin (Barc). 2017 May 1. pii: S0025-7753(17)30240-3. doi:10.1016/j.medcle.2017.02.030.

14. Kropacheva ES, Borovkov NN, Vavilova TV, et al. Rapid rates of saturation with warfarin is a predictor of the development of excessive hypocoagulation. Algorithm modernization for choosing a warfarin dose. Atherothrombosis. 2015;1:75-86. (In Russ.).